Paratek Pharma up on buyout deal for nearly $462 mln
06/06/2023 17:32
(Updates)
** Paratek Pharmaceuticals Inc's PRTK.O shares up 13.3% at
$2.2
** Drugmaker to be acquired by Gurnet Point Capital and Novo
Holdings in a transaction valued at nearly $462 mln
** All outstanding shares of PRTK will be acquired for
upfront payment of $2.15 per share in cash
** Offer also includes a contingent value right (CVR) of
$0.85, or a total potential value of $3.00 per share of common
stock
** CVR payable on achieving $320 mln in U.S. net sales for
PRTK's antibiotic drug Nuzyra in any calendar year ending on or
prior to Dec. 31, 2026
** Gurnet is a healthcare investment firm, and Novo
Holdings, to which Danish drugmaker Novo Nordisk NOVOb.CO is a
subsidiary, manages assets and wealth of Novo Nordisk Foundation
** Including session's gain, Paratek up 18.7% YTD
(Reporting by Pratik Jain in Bengaluru)
((Pratik.Jain@thomsonreuters.com))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million